Linda D Compton

Learn More
2042 Background: Oral irinotecan has the potential to safely and conveniently achieve protracted exposure of cycling tumor cells to SN-38 (irinotecan's active metabolite). The maximum tolerated dose(More)
PURPOSE This phase II, multicenter, open-label, single-arm study evaluated the efficacy and safety of irinotecan and gemcitabine as combination chemotherapy for previously untreated patients with(More)